Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only : the SIOP 93-01 and 2001 protocols
Purpose - Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the evidence for the treatment of patients relapsing after vincristine and actinomy...
Ausführliche Beschreibung
Autor*in: |
Groenendijk, Alissa [verfasserIn] van Tinteren, Harm [verfasserIn] Jiang, Yilin [verfasserIn] de Krijger, Ronald R. [verfasserIn] Vujanic, Gordan M. [verfasserIn] Godzinski, Jan [verfasserIn] Rübe, Christian [verfasserIn] Schenk, Jens-Peter [verfasserIn] Morosi, Carlo [verfasserIn] Pritchard-Jones, Kathy [verfasserIn] Al-Saadi, Reem [verfasserIn] Vaidya, Sucheta J. [verfasserIn] Verschuur, Arnauld C. [verfasserIn] Ramírez-Villar, Gema L. [verfasserIn] Graf, Norbert [verfasserIn] de Camargo, Beatriz [verfasserIn] Drost, Jarno [verfasserIn] Perotti, Daniela [verfasserIn] van den Heuvel-Eibrink, Marry M. [verfasserIn] Brok, Jesper [verfasserIn] Spreafico, Filippo [verfasserIn] Mavinkurve-Groothuis, Annelies M. C. [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
15 January 2022 |
---|
Schlagwörter: |
---|
Anmerkung: |
Gesehen am 01.07.2022 |
---|---|
Umfang: |
10 |
Übergeordnetes Werk: |
Enthalten in: European journal of cancer - Amsterdam [u.a.] : Elsevier, 1992, 163(2022) vom: März, Seite 88-97 |
---|---|
Übergeordnetes Werk: |
volume:163 ; year:2022 ; month:03 ; pages:88-97 ; extent:10 |
Links: |
---|
DOI / URN: |
10.1016/j.ejca.2021.12.014 |
---|
Katalog-ID: |
1808744187 |
---|
LEADER | 01000caa a2200265 4500 | ||
---|---|---|---|
001 | 1808744187 | ||
003 | DE-627 | ||
005 | 20240416193731.0 | ||
007 | cr uuu---uuuuu | ||
008 | 220701s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ejca.2021.12.014 |2 doi | |
035 | |a (DE-627)1808744187 | ||
035 | |a (DE-599)KXP1808744187 | ||
035 | |a (OCoLC)1341461900 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
100 | 1 | |a Groenendijk, Alissa |e verfasserin |0 (DE-588)1261569717 |0 (DE-627)1808745051 |4 aut | |
245 | 1 | 0 | |a Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only |b the SIOP 93-01 and 2001 protocols |c Alissa Groenendijk, Harm van Tinteren, Yilin Jiang, Ronald R. de Krijger, Gordan M. Vujanic, Jan Godzinski, Christian Rübe, Jens-Peter Schenk, Carlo Morosi, Kathy Pritchard-Jones, Reem Al-Saadi, Sucheta J. Vaidya, Arnauld C. Verschuur, Gema L. Ramírez-Villar, Norbert Graf, Beatriz de Camargo, Jarno Drost, Daniela Perotti, Marry M. van den Heuvel-Eibrink, Jesper Brok, Filippo Spreafico, Annelies M.C. Mavinkurve-Groothuis |
264 | 1 | |c 15 January 2022 | |
300 | |a 10 | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Gesehen am 01.07.2022 | ||
520 | |a Purpose - Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the evidence for the treatment of patients relapsing after vincristine and actinomycin-D (VA) treatment for primary WT, we retrospectively evaluated rescue treatment and survival of this patient group. - Patients and methods - We included 109 patients with relapse after VA therapy (no radiotherapy) for stage I-II primary low- or intermediate-risk WT from the SIOP 93-01 and SIOP 2001 studies. Univariate Cox regression analysis was performed to study the effect of relapse treatment intensity on event-free survival (EFS) and overall survival (OS). Relapse treatment intensity was classified into vincristine, actinomycin-D, and either doxorubicin or epirubicin (VAD), and more intensive therapies (ifosfamide/carboplatin/etoposide [ICE]/≥ 4 drugs/high-dose chemotherapy with haematopoietic stem cell transplantation [HD HSCT]). - Results - Relapse treatment regimens included either VAD, or cyclophosphamide/carboplatin/etoposide/doxorubicin (CyCED), or ICE backbones. Radiotherapy was administered in 62 patients and HD HSCT in 15 patients. Overall, 5-year EFS and OS after relapse were 72.3% (95% confidence interval [CI]: 64.0-81.6%) and 79.3% (95% CI: 71.5-88.0%), respectively. Patients treated with VAD did not fare worse when compared with patients treated with more intensive therapies (hazard ratio EFS: 0.611 [95% CI: 0.228-1.638] [p-value = 0.327] and hazard ratio OS: 0.438 [95% CI: 0.126-1.700] [p-value = 0.193]). - Conclusion - Patients with relapsed WT after initial VA-only treatment showed no inferior EFS and OS when treated with VAD regimens compared with more intensive rescue regimens. A subset of patients relapsing after VA may benefit from less intensive rescue treatment than ICE/CyCED-based regimens and deserve to be pinpointed by identifying additional (molecular) prognostic factors in future studies. | ||
650 | 4 | |a Recurrence | |
650 | 4 | |a SIOP protocol | |
650 | 4 | |a Treatment outcome | |
650 | 4 | |a Wilms tumour | |
700 | 1 | |a van Tinteren, Harm |e verfasserin |4 aut | |
700 | 1 | |a Jiang, Yilin |e verfasserin |4 aut | |
700 | 1 | |a de Krijger, Ronald R. |e verfasserin |4 aut | |
700 | 1 | |a Vujanic, Gordan M. |e verfasserin |4 aut | |
700 | 1 | |a Godzinski, Jan |e verfasserin |4 aut | |
700 | 1 | |a Rübe, Christian |e verfasserin |4 aut | |
700 | 1 | |a Schenk, Jens-Peter |e verfasserin |0 (DE-588)1055855114 |0 (DE-627)792738667 |0 (DE-576)260795577 |4 aut | |
700 | 1 | |a Morosi, Carlo |e verfasserin |4 aut | |
700 | 1 | |a Pritchard-Jones, Kathy |e verfasserin |4 aut | |
700 | 1 | |a Al-Saadi, Reem |e verfasserin |4 aut | |
700 | 1 | |a Vaidya, Sucheta J. |e verfasserin |4 aut | |
700 | 1 | |a Verschuur, Arnauld C. |e verfasserin |4 aut | |
700 | 1 | |a Ramírez-Villar, Gema L. |e verfasserin |4 aut | |
700 | 1 | |a Graf, Norbert |e verfasserin |4 aut | |
700 | 1 | |a de Camargo, Beatriz |e verfasserin |4 aut | |
700 | 1 | |a Drost, Jarno |e verfasserin |4 aut | |
700 | 1 | |a Perotti, Daniela |e verfasserin |4 aut | |
700 | 1 | |a van den Heuvel-Eibrink, Marry M. |e verfasserin |4 aut | |
700 | 1 | |a Brok, Jesper |e verfasserin |4 aut | |
700 | 1 | |a Spreafico, Filippo |e verfasserin |4 aut | |
700 | 1 | |a Mavinkurve-Groothuis, Annelies M. C. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 163(2022) vom: März, Seite 88-97 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnns |
773 | 1 | 8 | |g volume:163 |g year:2022 |g month:03 |g pages:88-97 |g extent:10 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2021.12.014 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804921012855 |x Verlag |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ILN_2013 | ||
912 | |a ISIL_DE-16-250 | ||
912 | |a SYSFLAG_1 | ||
912 | |a GBV_KXP | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2065 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4393 | ||
951 | |a AR | ||
952 | |d 163 |j 2022 |c 3 |h 88-97 |g 10 | ||
980 | |2 2013 |1 01 |x DE-16-250 |b 4159879888 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 01-07-22 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2022 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_22 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_10 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1481908154 |a Schenk, Jens-Peter | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416741399 |a Radiologische Universitätsklinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_8 |
author_variant |
a g ag t h v th thv y j yj k r r d krr krrd g m v gm gmv j g jg c r cr j p s jps c m cm k p j kpj r a s ras s j v sj sjv a c v ac acv g l r v glr glrv n g ng c b d cb cbd j d jd d p dp d h e m m v dhemm dhemmv j b jb f s fs a m c m g amcm amcmg |
---|---|
matchkey_str |
article:18790852:2022----::ucmosoptetwtlwrnemdaeikimtmurlpigfeiiilici |
oclc_num |
1341461900 |
hierarchy_sort_str |
15 January 2022 |
publishDate |
2022 |
allfields |
10.1016/j.ejca.2021.12.014 doi (DE-627)1808744187 (DE-599)KXP1808744187 (OCoLC)1341461900 DE-627 ger DE-627 rda eng Groenendijk, Alissa verfasserin (DE-588)1261569717 (DE-627)1808745051 aut Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only the SIOP 93-01 and 2001 protocols Alissa Groenendijk, Harm van Tinteren, Yilin Jiang, Ronald R. de Krijger, Gordan M. Vujanic, Jan Godzinski, Christian Rübe, Jens-Peter Schenk, Carlo Morosi, Kathy Pritchard-Jones, Reem Al-Saadi, Sucheta J. Vaidya, Arnauld C. Verschuur, Gema L. Ramírez-Villar, Norbert Graf, Beatriz de Camargo, Jarno Drost, Daniela Perotti, Marry M. van den Heuvel-Eibrink, Jesper Brok, Filippo Spreafico, Annelies M.C. Mavinkurve-Groothuis 15 January 2022 10 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Gesehen am 01.07.2022 Purpose - Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the evidence for the treatment of patients relapsing after vincristine and actinomycin-D (VA) treatment for primary WT, we retrospectively evaluated rescue treatment and survival of this patient group. - Patients and methods - We included 109 patients with relapse after VA therapy (no radiotherapy) for stage I-II primary low- or intermediate-risk WT from the SIOP 93-01 and SIOP 2001 studies. Univariate Cox regression analysis was performed to study the effect of relapse treatment intensity on event-free survival (EFS) and overall survival (OS). Relapse treatment intensity was classified into vincristine, actinomycin-D, and either doxorubicin or epirubicin (VAD), and more intensive therapies (ifosfamide/carboplatin/etoposide [ICE]/≥ 4 drugs/high-dose chemotherapy with haematopoietic stem cell transplantation [HD HSCT]). - Results - Relapse treatment regimens included either VAD, or cyclophosphamide/carboplatin/etoposide/doxorubicin (CyCED), or ICE backbones. Radiotherapy was administered in 62 patients and HD HSCT in 15 patients. Overall, 5-year EFS and OS after relapse were 72.3% (95% confidence interval [CI]: 64.0-81.6%) and 79.3% (95% CI: 71.5-88.0%), respectively. Patients treated with VAD did not fare worse when compared with patients treated with more intensive therapies (hazard ratio EFS: 0.611 [95% CI: 0.228-1.638] [p-value = 0.327] and hazard ratio OS: 0.438 [95% CI: 0.126-1.700] [p-value = 0.193]). - Conclusion - Patients with relapsed WT after initial VA-only treatment showed no inferior EFS and OS when treated with VAD regimens compared with more intensive rescue regimens. A subset of patients relapsing after VA may benefit from less intensive rescue treatment than ICE/CyCED-based regimens and deserve to be pinpointed by identifying additional (molecular) prognostic factors in future studies. Recurrence SIOP protocol Treatment outcome Wilms tumour van Tinteren, Harm verfasserin aut Jiang, Yilin verfasserin aut de Krijger, Ronald R. verfasserin aut Vujanic, Gordan M. verfasserin aut Godzinski, Jan verfasserin aut Rübe, Christian verfasserin aut Schenk, Jens-Peter verfasserin (DE-588)1055855114 (DE-627)792738667 (DE-576)260795577 aut Morosi, Carlo verfasserin aut Pritchard-Jones, Kathy verfasserin aut Al-Saadi, Reem verfasserin aut Vaidya, Sucheta J. verfasserin aut Verschuur, Arnauld C. verfasserin aut Ramírez-Villar, Gema L. verfasserin aut Graf, Norbert verfasserin aut de Camargo, Beatriz verfasserin aut Drost, Jarno verfasserin aut Perotti, Daniela verfasserin aut van den Heuvel-Eibrink, Marry M. verfasserin aut Brok, Jesper verfasserin aut Spreafico, Filippo verfasserin aut Mavinkurve-Groothuis, Annelies M. C. verfasserin aut Enthalten in European journal of cancer Amsterdam [u.a.] : Elsevier, 1992 163(2022) vom: März, Seite 88-97 (DE-627)266883400 (DE-600)1468190-0 (DE-576)090954173 1879-0852 nnns volume:163 year:2022 month:03 pages:88-97 extent:10 https://doi.org/10.1016/j.ejca.2021.12.014 Verlag Resolving-System lizenzpflichtig Volltext https://www.sciencedirect.com/science/article/pii/S0959804921012855 Verlag lizenzpflichtig Volltext GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 AR 163 2022 3 88-97 10 2013 01 DE-16-250 4159879888 00 --%%-- --%%-- --%%-- --%%-- l01 01-07-22 2013 01 DE-16-250 00 s hd2022 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_22 2013 01 DE-16-250 03 s s_10 2013 01 DE-16-250 04 p (DE-627)1481908154 Schenk, Jens-Peter 2013 01 DE-16-250 04 k (DE-627)1416741399 Radiologische Universitätsklinik 2013 01 DE-16-250 04 k (DE-627)1416466967 Medizinische Fakultät Heidelberg 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_8 |
spelling |
10.1016/j.ejca.2021.12.014 doi (DE-627)1808744187 (DE-599)KXP1808744187 (OCoLC)1341461900 DE-627 ger DE-627 rda eng Groenendijk, Alissa verfasserin (DE-588)1261569717 (DE-627)1808745051 aut Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only the SIOP 93-01 and 2001 protocols Alissa Groenendijk, Harm van Tinteren, Yilin Jiang, Ronald R. de Krijger, Gordan M. Vujanic, Jan Godzinski, Christian Rübe, Jens-Peter Schenk, Carlo Morosi, Kathy Pritchard-Jones, Reem Al-Saadi, Sucheta J. Vaidya, Arnauld C. Verschuur, Gema L. Ramírez-Villar, Norbert Graf, Beatriz de Camargo, Jarno Drost, Daniela Perotti, Marry M. van den Heuvel-Eibrink, Jesper Brok, Filippo Spreafico, Annelies M.C. Mavinkurve-Groothuis 15 January 2022 10 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Gesehen am 01.07.2022 Purpose - Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the evidence for the treatment of patients relapsing after vincristine and actinomycin-D (VA) treatment for primary WT, we retrospectively evaluated rescue treatment and survival of this patient group. - Patients and methods - We included 109 patients with relapse after VA therapy (no radiotherapy) for stage I-II primary low- or intermediate-risk WT from the SIOP 93-01 and SIOP 2001 studies. Univariate Cox regression analysis was performed to study the effect of relapse treatment intensity on event-free survival (EFS) and overall survival (OS). Relapse treatment intensity was classified into vincristine, actinomycin-D, and either doxorubicin or epirubicin (VAD), and more intensive therapies (ifosfamide/carboplatin/etoposide [ICE]/≥ 4 drugs/high-dose chemotherapy with haematopoietic stem cell transplantation [HD HSCT]). - Results - Relapse treatment regimens included either VAD, or cyclophosphamide/carboplatin/etoposide/doxorubicin (CyCED), or ICE backbones. Radiotherapy was administered in 62 patients and HD HSCT in 15 patients. Overall, 5-year EFS and OS after relapse were 72.3% (95% confidence interval [CI]: 64.0-81.6%) and 79.3% (95% CI: 71.5-88.0%), respectively. Patients treated with VAD did not fare worse when compared with patients treated with more intensive therapies (hazard ratio EFS: 0.611 [95% CI: 0.228-1.638] [p-value = 0.327] and hazard ratio OS: 0.438 [95% CI: 0.126-1.700] [p-value = 0.193]). - Conclusion - Patients with relapsed WT after initial VA-only treatment showed no inferior EFS and OS when treated with VAD regimens compared with more intensive rescue regimens. A subset of patients relapsing after VA may benefit from less intensive rescue treatment than ICE/CyCED-based regimens and deserve to be pinpointed by identifying additional (molecular) prognostic factors in future studies. Recurrence SIOP protocol Treatment outcome Wilms tumour van Tinteren, Harm verfasserin aut Jiang, Yilin verfasserin aut de Krijger, Ronald R. verfasserin aut Vujanic, Gordan M. verfasserin aut Godzinski, Jan verfasserin aut Rübe, Christian verfasserin aut Schenk, Jens-Peter verfasserin (DE-588)1055855114 (DE-627)792738667 (DE-576)260795577 aut Morosi, Carlo verfasserin aut Pritchard-Jones, Kathy verfasserin aut Al-Saadi, Reem verfasserin aut Vaidya, Sucheta J. verfasserin aut Verschuur, Arnauld C. verfasserin aut Ramírez-Villar, Gema L. verfasserin aut Graf, Norbert verfasserin aut de Camargo, Beatriz verfasserin aut Drost, Jarno verfasserin aut Perotti, Daniela verfasserin aut van den Heuvel-Eibrink, Marry M. verfasserin aut Brok, Jesper verfasserin aut Spreafico, Filippo verfasserin aut Mavinkurve-Groothuis, Annelies M. C. verfasserin aut Enthalten in European journal of cancer Amsterdam [u.a.] : Elsevier, 1992 163(2022) vom: März, Seite 88-97 (DE-627)266883400 (DE-600)1468190-0 (DE-576)090954173 1879-0852 nnns volume:163 year:2022 month:03 pages:88-97 extent:10 https://doi.org/10.1016/j.ejca.2021.12.014 Verlag Resolving-System lizenzpflichtig Volltext https://www.sciencedirect.com/science/article/pii/S0959804921012855 Verlag lizenzpflichtig Volltext GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 AR 163 2022 3 88-97 10 2013 01 DE-16-250 4159879888 00 --%%-- --%%-- --%%-- --%%-- l01 01-07-22 2013 01 DE-16-250 00 s hd2022 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_22 2013 01 DE-16-250 03 s s_10 2013 01 DE-16-250 04 p (DE-627)1481908154 Schenk, Jens-Peter 2013 01 DE-16-250 04 k (DE-627)1416741399 Radiologische Universitätsklinik 2013 01 DE-16-250 04 k (DE-627)1416466967 Medizinische Fakultät Heidelberg 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_8 |
allfields_unstemmed |
10.1016/j.ejca.2021.12.014 doi (DE-627)1808744187 (DE-599)KXP1808744187 (OCoLC)1341461900 DE-627 ger DE-627 rda eng Groenendijk, Alissa verfasserin (DE-588)1261569717 (DE-627)1808745051 aut Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only the SIOP 93-01 and 2001 protocols Alissa Groenendijk, Harm van Tinteren, Yilin Jiang, Ronald R. de Krijger, Gordan M. Vujanic, Jan Godzinski, Christian Rübe, Jens-Peter Schenk, Carlo Morosi, Kathy Pritchard-Jones, Reem Al-Saadi, Sucheta J. Vaidya, Arnauld C. Verschuur, Gema L. Ramírez-Villar, Norbert Graf, Beatriz de Camargo, Jarno Drost, Daniela Perotti, Marry M. van den Heuvel-Eibrink, Jesper Brok, Filippo Spreafico, Annelies M.C. Mavinkurve-Groothuis 15 January 2022 10 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Gesehen am 01.07.2022 Purpose - Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the evidence for the treatment of patients relapsing after vincristine and actinomycin-D (VA) treatment for primary WT, we retrospectively evaluated rescue treatment and survival of this patient group. - Patients and methods - We included 109 patients with relapse after VA therapy (no radiotherapy) for stage I-II primary low- or intermediate-risk WT from the SIOP 93-01 and SIOP 2001 studies. Univariate Cox regression analysis was performed to study the effect of relapse treatment intensity on event-free survival (EFS) and overall survival (OS). Relapse treatment intensity was classified into vincristine, actinomycin-D, and either doxorubicin or epirubicin (VAD), and more intensive therapies (ifosfamide/carboplatin/etoposide [ICE]/≥ 4 drugs/high-dose chemotherapy with haematopoietic stem cell transplantation [HD HSCT]). - Results - Relapse treatment regimens included either VAD, or cyclophosphamide/carboplatin/etoposide/doxorubicin (CyCED), or ICE backbones. Radiotherapy was administered in 62 patients and HD HSCT in 15 patients. Overall, 5-year EFS and OS after relapse were 72.3% (95% confidence interval [CI]: 64.0-81.6%) and 79.3% (95% CI: 71.5-88.0%), respectively. Patients treated with VAD did not fare worse when compared with patients treated with more intensive therapies (hazard ratio EFS: 0.611 [95% CI: 0.228-1.638] [p-value = 0.327] and hazard ratio OS: 0.438 [95% CI: 0.126-1.700] [p-value = 0.193]). - Conclusion - Patients with relapsed WT after initial VA-only treatment showed no inferior EFS and OS when treated with VAD regimens compared with more intensive rescue regimens. A subset of patients relapsing after VA may benefit from less intensive rescue treatment than ICE/CyCED-based regimens and deserve to be pinpointed by identifying additional (molecular) prognostic factors in future studies. Recurrence SIOP protocol Treatment outcome Wilms tumour van Tinteren, Harm verfasserin aut Jiang, Yilin verfasserin aut de Krijger, Ronald R. verfasserin aut Vujanic, Gordan M. verfasserin aut Godzinski, Jan verfasserin aut Rübe, Christian verfasserin aut Schenk, Jens-Peter verfasserin (DE-588)1055855114 (DE-627)792738667 (DE-576)260795577 aut Morosi, Carlo verfasserin aut Pritchard-Jones, Kathy verfasserin aut Al-Saadi, Reem verfasserin aut Vaidya, Sucheta J. verfasserin aut Verschuur, Arnauld C. verfasserin aut Ramírez-Villar, Gema L. verfasserin aut Graf, Norbert verfasserin aut de Camargo, Beatriz verfasserin aut Drost, Jarno verfasserin aut Perotti, Daniela verfasserin aut van den Heuvel-Eibrink, Marry M. verfasserin aut Brok, Jesper verfasserin aut Spreafico, Filippo verfasserin aut Mavinkurve-Groothuis, Annelies M. C. verfasserin aut Enthalten in European journal of cancer Amsterdam [u.a.] : Elsevier, 1992 163(2022) vom: März, Seite 88-97 (DE-627)266883400 (DE-600)1468190-0 (DE-576)090954173 1879-0852 nnns volume:163 year:2022 month:03 pages:88-97 extent:10 https://doi.org/10.1016/j.ejca.2021.12.014 Verlag Resolving-System lizenzpflichtig Volltext https://www.sciencedirect.com/science/article/pii/S0959804921012855 Verlag lizenzpflichtig Volltext GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 AR 163 2022 3 88-97 10 2013 01 DE-16-250 4159879888 00 --%%-- --%%-- --%%-- --%%-- l01 01-07-22 2013 01 DE-16-250 00 s hd2022 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_22 2013 01 DE-16-250 03 s s_10 2013 01 DE-16-250 04 p (DE-627)1481908154 Schenk, Jens-Peter 2013 01 DE-16-250 04 k (DE-627)1416741399 Radiologische Universitätsklinik 2013 01 DE-16-250 04 k (DE-627)1416466967 Medizinische Fakultät Heidelberg 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_8 |
allfieldsGer |
10.1016/j.ejca.2021.12.014 doi (DE-627)1808744187 (DE-599)KXP1808744187 (OCoLC)1341461900 DE-627 ger DE-627 rda eng Groenendijk, Alissa verfasserin (DE-588)1261569717 (DE-627)1808745051 aut Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only the SIOP 93-01 and 2001 protocols Alissa Groenendijk, Harm van Tinteren, Yilin Jiang, Ronald R. de Krijger, Gordan M. Vujanic, Jan Godzinski, Christian Rübe, Jens-Peter Schenk, Carlo Morosi, Kathy Pritchard-Jones, Reem Al-Saadi, Sucheta J. Vaidya, Arnauld C. Verschuur, Gema L. Ramírez-Villar, Norbert Graf, Beatriz de Camargo, Jarno Drost, Daniela Perotti, Marry M. van den Heuvel-Eibrink, Jesper Brok, Filippo Spreafico, Annelies M.C. Mavinkurve-Groothuis 15 January 2022 10 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Gesehen am 01.07.2022 Purpose - Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the evidence for the treatment of patients relapsing after vincristine and actinomycin-D (VA) treatment for primary WT, we retrospectively evaluated rescue treatment and survival of this patient group. - Patients and methods - We included 109 patients with relapse after VA therapy (no radiotherapy) for stage I-II primary low- or intermediate-risk WT from the SIOP 93-01 and SIOP 2001 studies. Univariate Cox regression analysis was performed to study the effect of relapse treatment intensity on event-free survival (EFS) and overall survival (OS). Relapse treatment intensity was classified into vincristine, actinomycin-D, and either doxorubicin or epirubicin (VAD), and more intensive therapies (ifosfamide/carboplatin/etoposide [ICE]/≥ 4 drugs/high-dose chemotherapy with haematopoietic stem cell transplantation [HD HSCT]). - Results - Relapse treatment regimens included either VAD, or cyclophosphamide/carboplatin/etoposide/doxorubicin (CyCED), or ICE backbones. Radiotherapy was administered in 62 patients and HD HSCT in 15 patients. Overall, 5-year EFS and OS after relapse were 72.3% (95% confidence interval [CI]: 64.0-81.6%) and 79.3% (95% CI: 71.5-88.0%), respectively. Patients treated with VAD did not fare worse when compared with patients treated with more intensive therapies (hazard ratio EFS: 0.611 [95% CI: 0.228-1.638] [p-value = 0.327] and hazard ratio OS: 0.438 [95% CI: 0.126-1.700] [p-value = 0.193]). - Conclusion - Patients with relapsed WT after initial VA-only treatment showed no inferior EFS and OS when treated with VAD regimens compared with more intensive rescue regimens. A subset of patients relapsing after VA may benefit from less intensive rescue treatment than ICE/CyCED-based regimens and deserve to be pinpointed by identifying additional (molecular) prognostic factors in future studies. Recurrence SIOP protocol Treatment outcome Wilms tumour van Tinteren, Harm verfasserin aut Jiang, Yilin verfasserin aut de Krijger, Ronald R. verfasserin aut Vujanic, Gordan M. verfasserin aut Godzinski, Jan verfasserin aut Rübe, Christian verfasserin aut Schenk, Jens-Peter verfasserin (DE-588)1055855114 (DE-627)792738667 (DE-576)260795577 aut Morosi, Carlo verfasserin aut Pritchard-Jones, Kathy verfasserin aut Al-Saadi, Reem verfasserin aut Vaidya, Sucheta J. verfasserin aut Verschuur, Arnauld C. verfasserin aut Ramírez-Villar, Gema L. verfasserin aut Graf, Norbert verfasserin aut de Camargo, Beatriz verfasserin aut Drost, Jarno verfasserin aut Perotti, Daniela verfasserin aut van den Heuvel-Eibrink, Marry M. verfasserin aut Brok, Jesper verfasserin aut Spreafico, Filippo verfasserin aut Mavinkurve-Groothuis, Annelies M. C. verfasserin aut Enthalten in European journal of cancer Amsterdam [u.a.] : Elsevier, 1992 163(2022) vom: März, Seite 88-97 (DE-627)266883400 (DE-600)1468190-0 (DE-576)090954173 1879-0852 nnns volume:163 year:2022 month:03 pages:88-97 extent:10 https://doi.org/10.1016/j.ejca.2021.12.014 Verlag Resolving-System lizenzpflichtig Volltext https://www.sciencedirect.com/science/article/pii/S0959804921012855 Verlag lizenzpflichtig Volltext GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 AR 163 2022 3 88-97 10 2013 01 DE-16-250 4159879888 00 --%%-- --%%-- --%%-- --%%-- l01 01-07-22 2013 01 DE-16-250 00 s hd2022 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_22 2013 01 DE-16-250 03 s s_10 2013 01 DE-16-250 04 p (DE-627)1481908154 Schenk, Jens-Peter 2013 01 DE-16-250 04 k (DE-627)1416741399 Radiologische Universitätsklinik 2013 01 DE-16-250 04 k (DE-627)1416466967 Medizinische Fakultät Heidelberg 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_8 |
allfieldsSound |
10.1016/j.ejca.2021.12.014 doi (DE-627)1808744187 (DE-599)KXP1808744187 (OCoLC)1341461900 DE-627 ger DE-627 rda eng Groenendijk, Alissa verfasserin (DE-588)1261569717 (DE-627)1808745051 aut Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only the SIOP 93-01 and 2001 protocols Alissa Groenendijk, Harm van Tinteren, Yilin Jiang, Ronald R. de Krijger, Gordan M. Vujanic, Jan Godzinski, Christian Rübe, Jens-Peter Schenk, Carlo Morosi, Kathy Pritchard-Jones, Reem Al-Saadi, Sucheta J. Vaidya, Arnauld C. Verschuur, Gema L. Ramírez-Villar, Norbert Graf, Beatriz de Camargo, Jarno Drost, Daniela Perotti, Marry M. van den Heuvel-Eibrink, Jesper Brok, Filippo Spreafico, Annelies M.C. Mavinkurve-Groothuis 15 January 2022 10 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Gesehen am 01.07.2022 Purpose - Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the evidence for the treatment of patients relapsing after vincristine and actinomycin-D (VA) treatment for primary WT, we retrospectively evaluated rescue treatment and survival of this patient group. - Patients and methods - We included 109 patients with relapse after VA therapy (no radiotherapy) for stage I-II primary low- or intermediate-risk WT from the SIOP 93-01 and SIOP 2001 studies. Univariate Cox regression analysis was performed to study the effect of relapse treatment intensity on event-free survival (EFS) and overall survival (OS). Relapse treatment intensity was classified into vincristine, actinomycin-D, and either doxorubicin or epirubicin (VAD), and more intensive therapies (ifosfamide/carboplatin/etoposide [ICE]/≥ 4 drugs/high-dose chemotherapy with haematopoietic stem cell transplantation [HD HSCT]). - Results - Relapse treatment regimens included either VAD, or cyclophosphamide/carboplatin/etoposide/doxorubicin (CyCED), or ICE backbones. Radiotherapy was administered in 62 patients and HD HSCT in 15 patients. Overall, 5-year EFS and OS after relapse were 72.3% (95% confidence interval [CI]: 64.0-81.6%) and 79.3% (95% CI: 71.5-88.0%), respectively. Patients treated with VAD did not fare worse when compared with patients treated with more intensive therapies (hazard ratio EFS: 0.611 [95% CI: 0.228-1.638] [p-value = 0.327] and hazard ratio OS: 0.438 [95% CI: 0.126-1.700] [p-value = 0.193]). - Conclusion - Patients with relapsed WT after initial VA-only treatment showed no inferior EFS and OS when treated with VAD regimens compared with more intensive rescue regimens. A subset of patients relapsing after VA may benefit from less intensive rescue treatment than ICE/CyCED-based regimens and deserve to be pinpointed by identifying additional (molecular) prognostic factors in future studies. Recurrence SIOP protocol Treatment outcome Wilms tumour van Tinteren, Harm verfasserin aut Jiang, Yilin verfasserin aut de Krijger, Ronald R. verfasserin aut Vujanic, Gordan M. verfasserin aut Godzinski, Jan verfasserin aut Rübe, Christian verfasserin aut Schenk, Jens-Peter verfasserin (DE-588)1055855114 (DE-627)792738667 (DE-576)260795577 aut Morosi, Carlo verfasserin aut Pritchard-Jones, Kathy verfasserin aut Al-Saadi, Reem verfasserin aut Vaidya, Sucheta J. verfasserin aut Verschuur, Arnauld C. verfasserin aut Ramírez-Villar, Gema L. verfasserin aut Graf, Norbert verfasserin aut de Camargo, Beatriz verfasserin aut Drost, Jarno verfasserin aut Perotti, Daniela verfasserin aut van den Heuvel-Eibrink, Marry M. verfasserin aut Brok, Jesper verfasserin aut Spreafico, Filippo verfasserin aut Mavinkurve-Groothuis, Annelies M. C. verfasserin aut Enthalten in European journal of cancer Amsterdam [u.a.] : Elsevier, 1992 163(2022) vom: März, Seite 88-97 (DE-627)266883400 (DE-600)1468190-0 (DE-576)090954173 1879-0852 nnns volume:163 year:2022 month:03 pages:88-97 extent:10 https://doi.org/10.1016/j.ejca.2021.12.014 Verlag Resolving-System lizenzpflichtig Volltext https://www.sciencedirect.com/science/article/pii/S0959804921012855 Verlag lizenzpflichtig Volltext GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 AR 163 2022 3 88-97 10 2013 01 DE-16-250 4159879888 00 --%%-- --%%-- --%%-- --%%-- l01 01-07-22 2013 01 DE-16-250 00 s hd2022 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_22 2013 01 DE-16-250 03 s s_10 2013 01 DE-16-250 04 p (DE-627)1481908154 Schenk, Jens-Peter 2013 01 DE-16-250 04 k (DE-627)1416741399 Radiologische Universitätsklinik 2013 01 DE-16-250 04 k (DE-627)1416466967 Medizinische Fakultät Heidelberg 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_8 |
language |
English |
source |
Enthalten in European journal of cancer 163(2022) vom: März, Seite 88-97 volume:163 year:2022 month:03 pages:88-97 extent:10 |
sourceStr |
Enthalten in European journal of cancer 163(2022) vom: März, Seite 88-97 volume:163 year:2022 month:03 pages:88-97 extent:10 |
format_phy_str_mv |
Article |
building |
2013:0 |
institution |
findex.gbv.de |
selectbib_iln_str_mv |
2013@01 |
topic_facet |
Recurrence SIOP protocol Treatment outcome Wilms tumour |
sw_local_iln_str_mv |
2013:hd2022 DE-16-250:hd2022 2013:wissenschaftlicher Artikel (Zeitschrift) DE-16-250:wissenschaftlicher Artikel (Zeitschrift) 2013:per_22 DE-16-250:per_22 2013:s_10 DE-16-250:s_10 2013:Schenk, Jens-Peter DE-16-250:Schenk, Jens-Peter 2013:Radiologische Universitätsklinik DE-16-250:Radiologische Universitätsklinik 2013:Medizinische Fakultät Heidelberg DE-16-250:Medizinische Fakultät Heidelberg 2013:Verfasser DE-16-250:Verfasser 2013:pos_8 DE-16-250:pos_8 |
isfreeaccess_bool |
false |
container_title |
European journal of cancer |
authorswithroles_txt_mv |
Groenendijk, Alissa @@aut@@ van Tinteren, Harm @@aut@@ Jiang, Yilin @@aut@@ de Krijger, Ronald R. @@aut@@ Vujanic, Gordan M. @@aut@@ Godzinski, Jan @@aut@@ Rübe, Christian @@aut@@ Schenk, Jens-Peter @@aut@@ Morosi, Carlo @@aut@@ Pritchard-Jones, Kathy @@aut@@ Al-Saadi, Reem @@aut@@ Vaidya, Sucheta J. @@aut@@ Verschuur, Arnauld C. @@aut@@ Ramírez-Villar, Gema L. @@aut@@ Graf, Norbert @@aut@@ de Camargo, Beatriz @@aut@@ Drost, Jarno @@aut@@ Perotti, Daniela @@aut@@ van den Heuvel-Eibrink, Marry M. @@aut@@ Brok, Jesper @@aut@@ Spreafico, Filippo @@aut@@ Mavinkurve-Groothuis, Annelies M. C. @@aut@@ |
publishDateDaySort_date |
2022-03-01T00:00:00Z |
hierarchy_top_id |
266883400 |
id |
1808744187 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a2200265 4500</leader><controlfield tag="001">1808744187</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240416193731.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220701s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejca.2021.12.014</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)1808744187</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KXP1808744187</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1341461900</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Groenendijk, Alissa</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1261569717</subfield><subfield code="0">(DE-627)1808745051</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only</subfield><subfield code="b">the SIOP 93-01 and 2001 protocols</subfield><subfield code="c">Alissa Groenendijk, Harm van Tinteren, Yilin Jiang, Ronald R. de Krijger, Gordan M. Vujanic, Jan Godzinski, Christian Rübe, Jens-Peter Schenk, Carlo Morosi, Kathy Pritchard-Jones, Reem Al-Saadi, Sucheta J. Vaidya, Arnauld C. Verschuur, Gema L. Ramírez-Villar, Norbert Graf, Beatriz de Camargo, Jarno Drost, Daniela Perotti, Marry M. van den Heuvel-Eibrink, Jesper Brok, Filippo Spreafico, Annelies M.C. Mavinkurve-Groothuis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">15 January 2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Gesehen am 01.07.2022</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose - Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the evidence for the treatment of patients relapsing after vincristine and actinomycin-D (VA) treatment for primary WT, we retrospectively evaluated rescue treatment and survival of this patient group. - Patients and methods - We included 109 patients with relapse after VA therapy (no radiotherapy) for stage I-II primary low- or intermediate-risk WT from the SIOP 93-01 and SIOP 2001 studies. Univariate Cox regression analysis was performed to study the effect of relapse treatment intensity on event-free survival (EFS) and overall survival (OS). Relapse treatment intensity was classified into vincristine, actinomycin-D, and either doxorubicin or epirubicin (VAD), and more intensive therapies (ifosfamide/carboplatin/etoposide [ICE]/≥ 4 drugs/high-dose chemotherapy with haematopoietic stem cell transplantation [HD HSCT]). - Results - Relapse treatment regimens included either VAD, or cyclophosphamide/carboplatin/etoposide/doxorubicin (CyCED), or ICE backbones. Radiotherapy was administered in 62 patients and HD HSCT in 15 patients. Overall, 5-year EFS and OS after relapse were 72.3% (95% confidence interval [CI]: 64.0-81.6%) and 79.3% (95% CI: 71.5-88.0%), respectively. Patients treated with VAD did not fare worse when compared with patients treated with more intensive therapies (hazard ratio EFS: 0.611 [95% CI: 0.228-1.638] [p-value = 0.327] and hazard ratio OS: 0.438 [95% CI: 0.126-1.700] [p-value = 0.193]). - Conclusion - Patients with relapsed WT after initial VA-only treatment showed no inferior EFS and OS when treated with VAD regimens compared with more intensive rescue regimens. A subset of patients relapsing after VA may benefit from less intensive rescue treatment than ICE/CyCED-based regimens and deserve to be pinpointed by identifying additional (molecular) prognostic factors in future studies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Recurrence</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SIOP protocol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment outcome</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Wilms tumour</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van Tinteren, Harm</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jiang, Yilin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Krijger, Ronald R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vujanic, Gordan M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Godzinski, Jan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rübe, Christian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schenk, Jens-Peter</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1055855114</subfield><subfield code="0">(DE-627)792738667</subfield><subfield code="0">(DE-576)260795577</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morosi, Carlo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pritchard-Jones, Kathy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Al-Saadi, Reem</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vaidya, Sucheta J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verschuur, Arnauld C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ramírez-Villar, Gema L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Graf, Norbert</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Camargo, Beatriz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Drost, Jarno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Perotti, Daniela</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van den Heuvel-Eibrink, Marry M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brok, Jesper</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Spreafico, Filippo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mavinkurve-Groothuis, Annelies M. C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">European journal of cancer</subfield><subfield code="d">Amsterdam [u.a.] : Elsevier, 1992</subfield><subfield code="g">163(2022) vom: März, Seite 88-97</subfield><subfield code="w">(DE-627)266883400</subfield><subfield code="w">(DE-600)1468190-0</subfield><subfield code="w">(DE-576)090954173</subfield><subfield code="x">1879-0852</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:163</subfield><subfield code="g">year:2022</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:88-97</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejca.2021.12.014</subfield><subfield code="x">Verlag</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.sciencedirect.com/science/article/pii/S0959804921012855</subfield><subfield code="x">Verlag</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2013</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ISIL_DE-16-250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_1</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_KXP</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">163</subfield><subfield code="j">2022</subfield><subfield code="c">3</subfield><subfield code="h">88-97</subfield><subfield code="g">10</subfield></datafield><datafield tag="980" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="b">4159879888</subfield><subfield code="c">00</subfield><subfield code="f">--%%--</subfield><subfield code="d">--%%--</subfield><subfield code="e">--%%--</subfield><subfield code="j">--%%--</subfield><subfield code="y">l01</subfield><subfield code="z">01-07-22</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">00</subfield><subfield code="s">s</subfield><subfield code="a">hd2022</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">01</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410508463</subfield><subfield code="a">wissenschaftlicher Artikel (Zeitschrift)</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">02</subfield><subfield code="s">s</subfield><subfield code="a">per_22</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">03</subfield><subfield code="s">s</subfield><subfield code="a">s_10</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1481908154</subfield><subfield code="a">Schenk, Jens-Peter</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416741399</subfield><subfield code="a">Radiologische Universitätsklinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416466967</subfield><subfield code="a">Medizinische Fakultät Heidelberg</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">s</subfield><subfield code="a">pos_8</subfield></datafield></record></collection>
|
standort_str_mv |
--%%-- |
standort_iln_str_mv |
2013:--%%-- DE-16-250:--%%-- |
author |
Groenendijk, Alissa |
spellingShingle |
Groenendijk, Alissa misc Recurrence misc SIOP protocol misc Treatment outcome misc Wilms tumour 2013 hd2022 2013 wissenschaftlicher Artikel (Zeitschrift) 2013 per_22 2013 s_10 2013 Schenk, Jens-Peter 2013 Radiologische Universitätsklinik 2013 Medizinische Fakultät Heidelberg 2013 Verfasser 2013 pos_8 Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only the SIOP 93-01 and 2001 protocols |
authorStr |
Groenendijk, Alissa |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)266883400 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
typewithnormlink_str_mv |
Person@(DE-588)1261569717 DifferentiatedPerson@(DE-588)1261569717 Person@(DE-588)1055855114 DifferentiatedPerson@(DE-588)1055855114 |
collection |
KXP SWB GVK |
remote_str |
true |
last_changed_iln_str_mv |
2013@01-07-22 |
illustrated |
Not Illustrated |
issn |
1879-0852 |
topic_title |
2013 01 DE-16-250 00 s hd2022 2013 01 DE-16-250 01 s (DE-627)1410508463 wissenschaftlicher Artikel (Zeitschrift) 2013 01 DE-16-250 02 s per_22 2013 01 DE-16-250 03 s s_10 2013 01 DE-16-250 04 p (DE-627)1481908154 Schenk, Jens-Peter 2013 01 DE-16-250 04 k (DE-627)1416741399 Radiologische Universitätsklinik 2013 01 DE-16-250 04 k (DE-627)1416466967 Medizinische Fakultät Heidelberg 2013 01 DE-16-250 04 s (DE-627)1410501914 Verfasser 2013 01 DE-16-250 04 s pos_8 Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only the SIOP 93-01 and 2001 protocols Alissa Groenendijk, Harm van Tinteren, Yilin Jiang, Ronald R. de Krijger, Gordan M. Vujanic, Jan Godzinski, Christian Rübe, Jens-Peter Schenk, Carlo Morosi, Kathy Pritchard-Jones, Reem Al-Saadi, Sucheta J. Vaidya, Arnauld C. Verschuur, Gema L. Ramírez-Villar, Norbert Graf, Beatriz de Camargo, Jarno Drost, Daniela Perotti, Marry M. van den Heuvel-Eibrink, Jesper Brok, Filippo Spreafico, Annelies M.C. Mavinkurve-Groothuis Recurrence SIOP protocol Treatment outcome Wilms tumour |
topic |
misc Recurrence misc SIOP protocol misc Treatment outcome misc Wilms tumour 2013 hd2022 2013 wissenschaftlicher Artikel (Zeitschrift) 2013 per_22 2013 s_10 2013 Schenk, Jens-Peter 2013 Radiologische Universitätsklinik 2013 Medizinische Fakultät Heidelberg 2013 Verfasser 2013 pos_8 |
topic_unstemmed |
misc Recurrence misc SIOP protocol misc Treatment outcome misc Wilms tumour 2013 hd2022 2013 wissenschaftlicher Artikel (Zeitschrift) 2013 per_22 2013 s_10 2013 Schenk, Jens-Peter 2013 Radiologische Universitätsklinik 2013 Medizinische Fakultät Heidelberg 2013 Verfasser 2013 pos_8 |
topic_browse |
misc Recurrence misc SIOP protocol misc Treatment outcome misc Wilms tumour 2013 hd2022 2013 wissenschaftlicher Artikel (Zeitschrift) 2013 per_22 2013 s_10 2013 Schenk, Jens-Peter 2013 Radiologische Universitätsklinik 2013 Medizinische Fakultät Heidelberg 2013 Verfasser 2013 pos_8 |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
standort_txtP_mv |
--%%-- |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
European journal of cancer |
normlinkwithtype_str_mv |
(DE-588)1261569717@Person (DE-588)1261569717@DifferentiatedPerson (DE-588)1055855114@Person (DE-588)1055855114@DifferentiatedPerson |
hierarchy_parent_id |
266883400 |
signature |
--%%-- |
signature_str_mv |
--%%-- |
hierarchy_top_title |
European journal of cancer |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)266883400 (DE-600)1468190-0 (DE-576)090954173 |
normlinkwithrole_str_mv |
(DE-588)1261569717@@aut@@ (DE-588)1055855114@@aut@@ |
title |
Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only the SIOP 93-01 and 2001 protocols |
ctrlnum |
(DE-627)1808744187 (DE-599)KXP1808744187 (OCoLC)1341461900 |
title_full |
Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only the SIOP 93-01 and 2001 protocols Alissa Groenendijk, Harm van Tinteren, Yilin Jiang, Ronald R. de Krijger, Gordan M. Vujanic, Jan Godzinski, Christian Rübe, Jens-Peter Schenk, Carlo Morosi, Kathy Pritchard-Jones, Reem Al-Saadi, Sucheta J. Vaidya, Arnauld C. Verschuur, Gema L. Ramírez-Villar, Norbert Graf, Beatriz de Camargo, Jarno Drost, Daniela Perotti, Marry M. van den Heuvel-Eibrink, Jesper Brok, Filippo Spreafico, Annelies M.C. Mavinkurve-Groothuis |
author_sort |
Groenendijk, Alissa |
journal |
European journal of cancer |
journalStr |
European journal of cancer |
callnumber-first-code |
- |
lang_code |
eng |
isOA_bool |
false |
recordtype |
marc |
publishDateSort |
2022 |
contenttype_str_mv |
txt |
container_start_page |
88 |
author_browse |
Groenendijk, Alissa van Tinteren, Harm Jiang, Yilin de Krijger, Ronald R. Vujanic, Gordan M. Godzinski, Jan Rübe, Christian Schenk, Jens-Peter Morosi, Carlo Pritchard-Jones, Kathy Al-Saadi, Reem Vaidya, Sucheta J. Verschuur, Arnauld C. Ramírez-Villar, Gema L. Graf, Norbert de Camargo, Beatriz Drost, Jarno Perotti, Daniela van den Heuvel-Eibrink, Marry M. Brok, Jesper Spreafico, Filippo Mavinkurve-Groothuis, Annelies M. C. |
selectkey |
2013:l |
container_volume |
163 |
physical |
10 |
format_se |
Elektronische Aufsätze |
author-letter |
Groenendijk, Alissa |
title_sub |
the SIOP 93-01 and 2001 protocols |
doi_str_mv |
10.1016/j.ejca.2021.12.014 |
normlink |
1261569717 1808745051 1055855114 792738667 260795577 1410508463 1481908154 1416741399 1416466967 1410501914 |
normlink_prefix_str_mv |
(DE-588)1261569717 (DE-627)1808745051 (DE-588)1055855114 (DE-627)792738667 (DE-576)260795577 (DE-627)1410508463 (DE-627)1481908154 (DE-627)1416741399 (DE-627)1416466967 (DE-627)1410501914 |
author2-role |
verfasserin |
title_sort |
outcome of siop patients with low- or intermediate-risk wilms tumour relapsing after initial vincristine and actinomycin-d therapy onlythe siop 93-01 and 2001 protocols |
title_auth |
Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only the SIOP 93-01 and 2001 protocols |
abstract |
Purpose - Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the evidence for the treatment of patients relapsing after vincristine and actinomycin-D (VA) treatment for primary WT, we retrospectively evaluated rescue treatment and survival of this patient group. - Patients and methods - We included 109 patients with relapse after VA therapy (no radiotherapy) for stage I-II primary low- or intermediate-risk WT from the SIOP 93-01 and SIOP 2001 studies. Univariate Cox regression analysis was performed to study the effect of relapse treatment intensity on event-free survival (EFS) and overall survival (OS). Relapse treatment intensity was classified into vincristine, actinomycin-D, and either doxorubicin or epirubicin (VAD), and more intensive therapies (ifosfamide/carboplatin/etoposide [ICE]/≥ 4 drugs/high-dose chemotherapy with haematopoietic stem cell transplantation [HD HSCT]). - Results - Relapse treatment regimens included either VAD, or cyclophosphamide/carboplatin/etoposide/doxorubicin (CyCED), or ICE backbones. Radiotherapy was administered in 62 patients and HD HSCT in 15 patients. Overall, 5-year EFS and OS after relapse were 72.3% (95% confidence interval [CI]: 64.0-81.6%) and 79.3% (95% CI: 71.5-88.0%), respectively. Patients treated with VAD did not fare worse when compared with patients treated with more intensive therapies (hazard ratio EFS: 0.611 [95% CI: 0.228-1.638] [p-value = 0.327] and hazard ratio OS: 0.438 [95% CI: 0.126-1.700] [p-value = 0.193]). - Conclusion - Patients with relapsed WT after initial VA-only treatment showed no inferior EFS and OS when treated with VAD regimens compared with more intensive rescue regimens. A subset of patients relapsing after VA may benefit from less intensive rescue treatment than ICE/CyCED-based regimens and deserve to be pinpointed by identifying additional (molecular) prognostic factors in future studies. Gesehen am 01.07.2022 |
abstractGer |
Purpose - Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the evidence for the treatment of patients relapsing after vincristine and actinomycin-D (VA) treatment for primary WT, we retrospectively evaluated rescue treatment and survival of this patient group. - Patients and methods - We included 109 patients with relapse after VA therapy (no radiotherapy) for stage I-II primary low- or intermediate-risk WT from the SIOP 93-01 and SIOP 2001 studies. Univariate Cox regression analysis was performed to study the effect of relapse treatment intensity on event-free survival (EFS) and overall survival (OS). Relapse treatment intensity was classified into vincristine, actinomycin-D, and either doxorubicin or epirubicin (VAD), and more intensive therapies (ifosfamide/carboplatin/etoposide [ICE]/≥ 4 drugs/high-dose chemotherapy with haematopoietic stem cell transplantation [HD HSCT]). - Results - Relapse treatment regimens included either VAD, or cyclophosphamide/carboplatin/etoposide/doxorubicin (CyCED), or ICE backbones. Radiotherapy was administered in 62 patients and HD HSCT in 15 patients. Overall, 5-year EFS and OS after relapse were 72.3% (95% confidence interval [CI]: 64.0-81.6%) and 79.3% (95% CI: 71.5-88.0%), respectively. Patients treated with VAD did not fare worse when compared with patients treated with more intensive therapies (hazard ratio EFS: 0.611 [95% CI: 0.228-1.638] [p-value = 0.327] and hazard ratio OS: 0.438 [95% CI: 0.126-1.700] [p-value = 0.193]). - Conclusion - Patients with relapsed WT after initial VA-only treatment showed no inferior EFS and OS when treated with VAD regimens compared with more intensive rescue regimens. A subset of patients relapsing after VA may benefit from less intensive rescue treatment than ICE/CyCED-based regimens and deserve to be pinpointed by identifying additional (molecular) prognostic factors in future studies. Gesehen am 01.07.2022 |
abstract_unstemmed |
Purpose - Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the evidence for the treatment of patients relapsing after vincristine and actinomycin-D (VA) treatment for primary WT, we retrospectively evaluated rescue treatment and survival of this patient group. - Patients and methods - We included 109 patients with relapse after VA therapy (no radiotherapy) for stage I-II primary low- or intermediate-risk WT from the SIOP 93-01 and SIOP 2001 studies. Univariate Cox regression analysis was performed to study the effect of relapse treatment intensity on event-free survival (EFS) and overall survival (OS). Relapse treatment intensity was classified into vincristine, actinomycin-D, and either doxorubicin or epirubicin (VAD), and more intensive therapies (ifosfamide/carboplatin/etoposide [ICE]/≥ 4 drugs/high-dose chemotherapy with haematopoietic stem cell transplantation [HD HSCT]). - Results - Relapse treatment regimens included either VAD, or cyclophosphamide/carboplatin/etoposide/doxorubicin (CyCED), or ICE backbones. Radiotherapy was administered in 62 patients and HD HSCT in 15 patients. Overall, 5-year EFS and OS after relapse were 72.3% (95% confidence interval [CI]: 64.0-81.6%) and 79.3% (95% CI: 71.5-88.0%), respectively. Patients treated with VAD did not fare worse when compared with patients treated with more intensive therapies (hazard ratio EFS: 0.611 [95% CI: 0.228-1.638] [p-value = 0.327] and hazard ratio OS: 0.438 [95% CI: 0.126-1.700] [p-value = 0.193]). - Conclusion - Patients with relapsed WT after initial VA-only treatment showed no inferior EFS and OS when treated with VAD regimens compared with more intensive rescue regimens. A subset of patients relapsing after VA may benefit from less intensive rescue treatment than ICE/CyCED-based regimens and deserve to be pinpointed by identifying additional (molecular) prognostic factors in future studies. Gesehen am 01.07.2022 |
collection_details |
GBV_USEFLAG_U GBV_ILN_2013 ISIL_DE-16-250 SYSFLAG_1 GBV_KXP SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 |
title_short |
Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only |
url |
https://doi.org/10.1016/j.ejca.2021.12.014 https://www.sciencedirect.com/science/article/pii/S0959804921012855 |
ausleihindikator_str_mv |
2013:- |
rolewithnormlink_str_mv |
@@aut@@(DE-588)1261569717 @@aut@@(DE-588)1055855114 |
remote_bool |
true |
author2 |
van Tinteren, Harm Jiang, Yilin de Krijger, Ronald R. Vujanic, Gordan M. Godzinski, Jan Rübe, Christian Schenk, Jens-Peter Morosi, Carlo Pritchard-Jones, Kathy Al-Saadi, Reem Vaidya, Sucheta J. Verschuur, Arnauld C. Ramírez-Villar, Gema L. Graf, Norbert de Camargo, Beatriz Drost, Jarno Perotti, Daniela van den Heuvel-Eibrink, Marry M. Brok, Jesper Spreafico, Filippo Mavinkurve-Groothuis, Annelies M. C. |
author2Str |
van Tinteren, Harm Jiang, Yilin de Krijger, Ronald R. Vujanic, Gordan M. Godzinski, Jan Rübe, Christian Schenk, Jens-Peter Morosi, Carlo Pritchard-Jones, Kathy Al-Saadi, Reem Vaidya, Sucheta J. Verschuur, Arnauld C. Ramírez-Villar, Gema L. Graf, Norbert de Camargo, Beatriz Drost, Jarno Perotti, Daniela van den Heuvel-Eibrink, Marry M. Brok, Jesper Spreafico, Filippo Mavinkurve-Groothuis, Annelies M. C. |
ppnlink |
266883400 |
GND_str_mv |
Groenendijk, Alissa Schenk, J.-P. Schenk, Jens Peter Schenk, Jens-Peter |
GND_txt_mv |
Groenendijk, Alissa Schenk, J.-P. Schenk, Jens Peter Schenk, Jens-Peter |
GND_txtF_mv |
Groenendijk, Alissa Schenk, J.-P. Schenk, Jens Peter Schenk, Jens-Peter |
mediatype_str_mv |
c |
isOA_txt |
false |
hochschulschrift_bool |
false |
doi_str |
10.1016/j.ejca.2021.12.014 |
callnumber-a |
--%%-- |
up_date |
2024-07-04T22:57:28.961Z |
_version_ |
1803691070811275264 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a2200265 4500</leader><controlfield tag="001">1808744187</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240416193731.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220701s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejca.2021.12.014</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)1808744187</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KXP1808744187</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1341461900</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Groenendijk, Alissa</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1261569717</subfield><subfield code="0">(DE-627)1808745051</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only</subfield><subfield code="b">the SIOP 93-01 and 2001 protocols</subfield><subfield code="c">Alissa Groenendijk, Harm van Tinteren, Yilin Jiang, Ronald R. de Krijger, Gordan M. Vujanic, Jan Godzinski, Christian Rübe, Jens-Peter Schenk, Carlo Morosi, Kathy Pritchard-Jones, Reem Al-Saadi, Sucheta J. Vaidya, Arnauld C. Verschuur, Gema L. Ramírez-Villar, Norbert Graf, Beatriz de Camargo, Jarno Drost, Daniela Perotti, Marry M. van den Heuvel-Eibrink, Jesper Brok, Filippo Spreafico, Annelies M.C. Mavinkurve-Groothuis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">15 January 2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Gesehen am 01.07.2022</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose - Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the evidence for the treatment of patients relapsing after vincristine and actinomycin-D (VA) treatment for primary WT, we retrospectively evaluated rescue treatment and survival of this patient group. - Patients and methods - We included 109 patients with relapse after VA therapy (no radiotherapy) for stage I-II primary low- or intermediate-risk WT from the SIOP 93-01 and SIOP 2001 studies. Univariate Cox regression analysis was performed to study the effect of relapse treatment intensity on event-free survival (EFS) and overall survival (OS). Relapse treatment intensity was classified into vincristine, actinomycin-D, and either doxorubicin or epirubicin (VAD), and more intensive therapies (ifosfamide/carboplatin/etoposide [ICE]/≥ 4 drugs/high-dose chemotherapy with haematopoietic stem cell transplantation [HD HSCT]). - Results - Relapse treatment regimens included either VAD, or cyclophosphamide/carboplatin/etoposide/doxorubicin (CyCED), or ICE backbones. Radiotherapy was administered in 62 patients and HD HSCT in 15 patients. Overall, 5-year EFS and OS after relapse were 72.3% (95% confidence interval [CI]: 64.0-81.6%) and 79.3% (95% CI: 71.5-88.0%), respectively. Patients treated with VAD did not fare worse when compared with patients treated with more intensive therapies (hazard ratio EFS: 0.611 [95% CI: 0.228-1.638] [p-value = 0.327] and hazard ratio OS: 0.438 [95% CI: 0.126-1.700] [p-value = 0.193]). - Conclusion - Patients with relapsed WT after initial VA-only treatment showed no inferior EFS and OS when treated with VAD regimens compared with more intensive rescue regimens. A subset of patients relapsing after VA may benefit from less intensive rescue treatment than ICE/CyCED-based regimens and deserve to be pinpointed by identifying additional (molecular) prognostic factors in future studies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Recurrence</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SIOP protocol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment outcome</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Wilms tumour</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van Tinteren, Harm</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jiang, Yilin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Krijger, Ronald R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vujanic, Gordan M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Godzinski, Jan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rübe, Christian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schenk, Jens-Peter</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(DE-588)1055855114</subfield><subfield code="0">(DE-627)792738667</subfield><subfield code="0">(DE-576)260795577</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morosi, Carlo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pritchard-Jones, Kathy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Al-Saadi, Reem</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vaidya, Sucheta J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verschuur, Arnauld C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ramírez-Villar, Gema L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Graf, Norbert</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Camargo, Beatriz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Drost, Jarno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Perotti, Daniela</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van den Heuvel-Eibrink, Marry M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brok, Jesper</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Spreafico, Filippo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mavinkurve-Groothuis, Annelies M. C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">European journal of cancer</subfield><subfield code="d">Amsterdam [u.a.] : Elsevier, 1992</subfield><subfield code="g">163(2022) vom: März, Seite 88-97</subfield><subfield code="w">(DE-627)266883400</subfield><subfield code="w">(DE-600)1468190-0</subfield><subfield code="w">(DE-576)090954173</subfield><subfield code="x">1879-0852</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:163</subfield><subfield code="g">year:2022</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:88-97</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejca.2021.12.014</subfield><subfield code="x">Verlag</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.sciencedirect.com/science/article/pii/S0959804921012855</subfield><subfield code="x">Verlag</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2013</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ISIL_DE-16-250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_1</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_KXP</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">163</subfield><subfield code="j">2022</subfield><subfield code="c">3</subfield><subfield code="h">88-97</subfield><subfield code="g">10</subfield></datafield><datafield tag="980" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="b">4159879888</subfield><subfield code="c">00</subfield><subfield code="f">--%%--</subfield><subfield code="d">--%%--</subfield><subfield code="e">--%%--</subfield><subfield code="j">--%%--</subfield><subfield code="y">l01</subfield><subfield code="z">01-07-22</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">00</subfield><subfield code="s">s</subfield><subfield code="a">hd2022</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">01</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410508463</subfield><subfield code="a">wissenschaftlicher Artikel (Zeitschrift)</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">02</subfield><subfield code="s">s</subfield><subfield code="a">per_22</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">03</subfield><subfield code="s">s</subfield><subfield code="a">s_10</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">p</subfield><subfield code="0">(DE-627)1481908154</subfield><subfield code="a">Schenk, Jens-Peter</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416741399</subfield><subfield code="a">Radiologische Universitätsklinik</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">k</subfield><subfield code="0">(DE-627)1416466967</subfield><subfield code="a">Medizinische Fakultät Heidelberg</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">s</subfield><subfield code="0">(DE-627)1410501914</subfield><subfield code="a">Verfasser</subfield></datafield><datafield tag="982" ind1=" " ind2=" "><subfield code="2">2013</subfield><subfield code="1">01</subfield><subfield code="x">DE-16-250</subfield><subfield code="8">04</subfield><subfield code="s">s</subfield><subfield code="a">pos_8</subfield></datafield></record></collection>
|
score |
7.397979 |